Community-led Responses for Elimination (CoRE): a study protocol for a community randomized controlled trial assessing the effectiveness of community-level, reactive focal drug administration for reducing Plasmodium falciparum infection prevalence and incidence in Southern Province, Zambia.

Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Antimalarials/*administration & dosage ; Artemisinins/*administration & dosage ; Ethanolamines/*administration & dosage ; Fluorenes/*administration & dosage ; Malaria, Falciparum/*prevention & control ; Plasmodium falciparum/*drug effects ; Quinolines/*administration & dosage; Adolescent ; Adult ; Antimalarials/adverse effects ; Artemether, Lumefantrine Drug Combination ; Artemisinins/adverse effects ; Child ; Child, Preschool ; Clinical Protocols ; Community Health Services ; Drug Administration Schedule ; Drug Combinations ; Ethanolamines/adverse effects ; Female ; Fluorenes/adverse effects ; Humans ; Incidence ; Infant ; Malaria, Falciparum/diagnosis ; Malaria, Falciparum/epidemiology ; Malaria, Falciparum/parasitology ; Male ; Middle Aged ; Plasmodium falciparum/pathogenicity ; Prevalence ; Quinolines/adverse effects ; Research Design ; Risk Factors ; Time Factors ; Treatment Outcome ; Young Adult ; Zambia/epidemiology

Background: Zambia is pushing for, and has made great strides towards, the elimination of malaria transmission in Southern Province. Reactive focal test and treat (RFTAT) using rapid diagnostic tests and artemether-lumefantrine (AL) has been key in making this progress. Reactive focal drug administration (RFDA) using dihydroartemisinin-piperaquine (DHAP), may be superior in accelerating clearance of the parasite reservoir in humans due to the provision of enhanced chemoprophylactic protection of at-risk populations against new infections. The primary aim of this study is to quantify the relative effectiveness of RFDA with DHAP against RFTAT with AL (standard of care) for reducing Plasmodium falciparum prevalence and incidence.
Methods/design: The study will be conducted in four districts in Southern Province, Zambia; an area of low malaria transmission and high coverage of vector control. A community randomized controlled trial of 16 health facility catchment areas will be used to evaluate the impact of sustained year-round routine RFDA for 2 years, relative to a control of year-round routine RFTAT. Reactive case detection will be triggered by a confirmed malaria case, e.g., by microscopy or rapid diagnostic test at any government health facility. Reactive responses will be performed by community health workers (CHW) within 7 days of the index case confirmation date. Responses will be performed out to a radius of 140 m from the index case household. A subset of responses will be followed longitudinally for 90 days to examine reinfection rates. Primary outcomes include a post-intervention survey of malaria seropositivity (n = 4800 children aged 1 month to under 5 years old) and a difference-in-differences analysis of malaria parasite incidence, as measured through routine passive case detection at health facilities enrolled in the study. The study is powered to detect approximately a 65% relative reduction in these outcomes between the intervention versus the control.
Discussion: Strengths of this trial include a robust study design and an endline cross-sectional parasite survey as well as a longitudinal sample. Primary limitations include statistical power to detect only a 65% reduction in primary outcomes, and the potential for contamination to dilute the effects of the intervention.
Trial Registration: ClinicalTrials.gov, ID: NCT02654912 . Registered on 12 November 2015.

Trop Med Int Health. 2009 Jan;14(1):70-8. (PMID: 19121149)
Am J Trop Med Hyg. 2015 May;92(5):913-21. (PMID: 25802434)
Malar J. 2012 Mar 28;11:93. (PMID: 22455864)
Int J Health Geogr. 2010 Nov 05;9:58. (PMID: 21050496)
Lancet. 2010 Nov 6;376(9752):1592-603. (PMID: 21035841)
PLoS Med. 2012 Jan;9(1):e1001165. (PMID: 22303287)
Malar J. 2015 Oct 22;14:416. (PMID: 26492873)
Int J Health Geogr. 2013 Jan 10;12:1. (PMID: 23305074)
Trends Parasitol. 2003 Oct;19(10):452-60. (PMID: 14519583)
Int J Epidemiol. 1999 Apr;28(2):319-26. (PMID: 10342698)
Med J Aust. 2005 Feb 21;182(4):181-5. (PMID: 15720175)
Malar J. 2010 Apr 15;9:96. (PMID: 20398318)
J Infect Dis. 2016 Dec 15;214(12 ):1831-1839. (PMID: 27923947)
J Med Microbiol. 2013 Oct;62(Pt 10):1491-505. (PMID: 24048274)
PLoS One. 2013 Apr 04;8(4):e60780. (PMID: 23593309)
Adv Parasitol. 2009;69:299-352. (PMID: 19622411)
Genetics. 2005 Jul;170(3):1261-80. (PMID: 15520263)
Malar J. 2012 Mar 25;11:86. (PMID: 22443375)
PLoS Comput Biol. 2014 Jan;10(1):e1003434. (PMID: 24465196)
Antimicrob Agents Chemother. 2000 Mar;44(3):697-704. (PMID: 10681341)
Int J Health Geogr. 2012 Mar 23;11:8. (PMID: 22443452)
PLoS One. 2011;6(5):e20179. (PMID: 21629651)
Nat Commun. 2012;3:1237. (PMID: 23212366)
Parasit Vectors. 2013 Jan 16;6:14. (PMID: 23324389)
Bull World Health Organ. 2014 Sep 1;92(9):690-4. (PMID: 25378761)
Malar J. 2008 Oct 29;7:223. (PMID: 18959790)
Lancet. 2000 Nov 4;356(9241):1560-4. (PMID: 11075770)
Drugs. 2005;65(1):75-87. (PMID: 15610051)
Malar J. 2010 Oct 04;9:265. (PMID: 20920328)
J Infect Dis. 2009 Nov 15;200(10):1509-17. (PMID: 19848588)
Malar J. 2013 Nov 01;12:383. (PMID: 24175930)
Malar J. 2015 Jan 19;14:4. (PMID: 25599890)
Malar J. 2016 Aug 11;15(1):408. (PMID: 27515533)
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5108-13. (PMID: 15792998)
Cochrane Database Syst Rev. 2013 Dec 09;(12):CD008846. (PMID: 24318836)
Trials. 2015 Aug 13;16:347. (PMID: 26268804)
Malar J. 2015 Nov 19;14:465. (PMID: 26586264)

ClinicalTrials.gov NCT02654912

0 (Antimalarials)
0 (Artemether, Lumefantrine Drug Combination)
0 (Artemisinins)
0 (Drug Combinations)
0 (Ethanolamines)
0 (Fluorenes)
0 (Quinolines)
6A9O50735X (artenimol)
A0HV2Q956Y (piperaquine)

Date Created: 20171104 Date Completed: 20180702 Latest Revision: 20210915

20240104

PMC5667476

10.1186/s13063-017-2249-0

29096671